vizgen.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $422.73MM
Vizgen, founded in 2019, is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPE Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/09/2024 | Series D-2 | $24MM | $xx.xx | $263.31MM | Arch Venture Partners, Northpond Ventures, Tao Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
93,734,220
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Northpond Ventures, Tao Capital Partners
|
||||||
10/09/2024 | Series D-3 | $74.35MM | $xx.xx | $263.31MM | Arch Venture Partners, Northpond Ventures, Tao Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
290,344,693
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Northpond Ventures, Tao Capital Partners
|
||||||
10/09/2024 | Series D-1 | $51.99MM | $xx.xx | $263.31MM | Arch Venture Partners, Northpond Ventures, Tao Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
157,571,747
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Northpond Ventures, Tao Capital Partners
|
||||||
06/03/2022 | Series C | $85.2MM | $xx.xx | $384.28MM | Arch Venture Partners, Blue Water Life Science Advisors, David Walt, Northpond Ventures, Novalis Lifesciences, Sofina, Tao Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
7,456,808
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
6.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Blue Water Life Science Advisors, David Walt, Northpond Ventures, Novalis Lifesciences, Sofina, Tao Capital Partners
|
||||||
04/07/2021 | Series B | $37MM | $xx.xx | $143.13MM | Arch Venture Partners, David Walt, Northpond Ventures, Novalis Lifesciences, Pura Vida Investments, Tao Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
6,517,297
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
5.2x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, David Walt, Northpond Ventures, Novalis Lifesciences, Pura Vida Investments, Tao Capital Partners
|
||||||
01/30/2020 | Series A | $14MM | $xx.xx | $31.11MM | Arch Venture Partners, Northpond Ventures | |
Price per Share
$xx.xx
Shares Outstanding
7,349,080
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
3.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Northpond Ventures
|